About
NeuroSigma, Inc. is a Los Angeles-based bioelectronics company commercializing external trigeminal nerve stimulation (eTNS) technology. NeuroSigma's Monarch eTNS® System is a bioelectronic medical device that uses external trigeminal nerve stimulation to treat neurological and neuropsychiatric disorders. In 2019, the Monarch eTNS System became the first-ever medical device cleared by FDA for treating pediatric ADHD. The new Monarch Pediatric Care Co-Pay Program is making eTNS therapy available to a substantially greater number of children diagnosed with ADHD.
Technologies
Cloudflare DNS
Sendgrid
Outlook
Microsoft Office 365
CloudFlare Hosting
Typekit
reCAPTCHA
Google Analytics
RegOnline
Google Tag Manager
Render
Remote
Keywords
biotechnology
life sciences
medical equipment manufacturing
depression
healthcare equipment & supplies
clinical research
neuromodulation for neurodevelopmental disorders
ptsd
non-invasive neuromodulation
epilepsy
neurological disorders
medical devices
monarch etns
medical equipment and supplies manufacturing
caregiver supervision
fda cleared device
neuropsychiatric disorders
healthcare technology
medical technology
bioelectronic medical device
clinical trial collaborations
neurotechnology innovation
pediatric adhd treatment
neurostimulation for adhd
neurosigma pipeline
patient care
etns system
neuromodulation
pediatric adhd
neuromodulation patents
Company Information
-
Employees 7
-
Founded 2008
-
Annual Revenue $3000000
-
Total Funding $17603514
Location
10960 Wilshire Blvd, Los Angeles, California, United States, 90024
